

Research Article

Potent *In Vitro* Phosphodiesterase 1 Inhibition of Flavone Isolated from *Pistacia integerrima* Galls

Abdur Rauf ¹, Sami Bawazeer,² Jesús Herrera-Bravo ^{3,4}, Muslim Raza,⁵ Humaira Naz,⁶ Somia Gul ⁷, Naveed Muhammad,⁸ Zainab M. Almarhoon ⁹, Yahia N. Mabkhot,¹⁰ Mohamed Fawzy Ramadan,¹¹ William N. Setzer,^{12,13} Sevgi Durna Daştan,^{14,15} Shafi Mahmud,¹⁶ and Javad Sharifi-Rad ¹⁷

¹Department of Chemistry, University of Swabi Anbar, 23430 Khyber Pakhtunkhwa, Pakistan

²Department of Pharmacognosy, Faculty of Pharmacy, Umm Al-Qura University, Makkah, P.O. Box 42, Saudi Arabia

³Departamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomas, Chile

⁴Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco 4811230, Chile

⁵Departments of Chemistry, Bacha Khan University Charsadda, Khyber Pakhtunkhwa, Pakistan

⁶Department of Zoology, Shaheed Benazir Bhutto Women University, Peshawar 2520, Pakistan

⁷Faculty of Pharmacy, Jinnah University for Woman, Karachi, Pakistan

⁸Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan

⁹Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia

¹⁰Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, Saudi Arabia

¹¹Deanship of Scientific Research, Umm Al-Qura University, Makkah, Saudi Arabia

¹²Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA

¹³Aromatic Plant Research Center, 230 N 1200 E, Suite 100, Lehi, UT 84043, USA

¹⁴Department of Biology, Faculty of Science, Sivas Cumhuriyet University, 58140 Sivas, Turkey

¹⁵Beekeeping Development Application and Research Center, Sivas Cumhuriyet University, 58140 Sivas, Turkey

¹⁶Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh

¹⁷Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador

Correspondence should be addressed to Abdur Rauf; mashaljc@yahoo.com and Javad Sharifi-Rad; javad.sharifrad@gmail.com

Received 2 September 2021; Revised 28 November 2021; Accepted 24 December 2021; Published 17 January 2022

Academic Editor: Stefano Pascarella

Copyright © 2022 Abdur Rauf et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

To prospect an isozyme-specific, effective inhibitor against the physiologically-crucial enzyme phosphodiesterase 1 (PDE1), phytochemicals from *Pistacia integerrima* galls were screened. The chloroform fraction of gall extract was subjected to column chromatographic which led to the isolation of compound **1**, elucidated to be 5-hydroxy-7-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one (a flavone). *In vitro* and *in silico* PDE1 inhibitory activity of the compound **1** was investigated. EDTA, a known PDE1 inhibitor, was used as the reference. The flavone exhibited *in vitro* attenuation towards snake venom PDE1. IC₅₀ response was superior to the standard chelator. An *in silico* molecular docking study was carried out using 3D structure of PDE1 to study the binding interactions of compound **1**. The docking study predicted that flavone had a lower binding affinity (-7.6 kcal/mol) and total energy (-95 kcal/mol) score compared to EDTA. The minimal energy associated with the ligand-protein complex implied that isolated compound **1** can serve as a therapeutic agent against PDE1 enzyme-provoked ailments like asthma, hypertension, schizophrenia, and erectile dysfunction.

1. Introduction

Pistacia integerrima J. L. Stewart ex Brandis, a member of the Anacardiaceae, is a species of pistachio tree, called zebra-wood, native to Asia [1]. This medium-sized, deciduous tree grows at lower elevations (800-2400 m) of certain parts of the Himalayas [2]. The plant parts have been used to ameliorate fever, asthma, chronic bronchitis, dysentery, diarrhea, wounds, indigestion, jaundice, and worms [3]. The barks, leaves, and roots of *P. integerrima* have demonstrated efficacy against a range of maladies. The biological potency of *P. integerrima* galls developing on the leaves and petioles induced by an aphid *Pemphigus* sp. is interesting [4]. The hard and hollow galls have been verified to be a storehouse of functional compounds. The profusion of bioactive secondary metabolites in the galled tissue compared to normal plant tissues has been observed [5]. Ethyl acetate extract of *P. integerrima* plant exhibited high DPPH^{*} radical-scavenging potential and demonstrated dose-dependent uric acid-lowering effect in hyperuricemic mice [6]. Extract of *P. integerrima* was active against many Gram-positive and two Gram-negative pathogens [7]. An active constituent of *P. integerrima* gall was identified as ethyl gallate. This ethyl ester of gallic acid lowered lipopolysaccharide-induced cell adhesion molecule (CAM) expression by blocking activator protein 1 (AP-1) transcription factor [8]. A triterpene, pistagremic acid (PA) isolated from the galls exhibited strong leishmanicidal activity, wherein the lethality against *Leishmania* major promastigotes was less than amphotericin B [9]. PA attenuated the activity of both yeast and rat intestinal α -glucosidases [10]. Intraperitoneal administration of PA (10 mg/kg) was shown to exhibit antinociceptive effect in the acetic acid-induced writhing test. In the tail immersion test, pretreatment with the triterpene (10 mg/kg), pain reduction was 59.4%. Additionally, it alleviated carrageenan-induced edema. Antipyretic effect was observed for 10 mg/kg administration to mice. A molecular docking study revealed that PA fits well in the active site of COX-2 enzyme due to hydrogen-bonding and hydrophobic moiety interactions [10, 11].

An *in vitro* study exhibited the antiradical potential of solvent fractions of *P. integerrima* leaf ethanol extract [12]. Essential oil of the galls in the treatment of bronchial asthma is possibly related to its ability to inhibit L-subtype Cav channel, mast cell stabilization, antioxidant, angiogenesis, and the inhibition of 5-lipoxygenase [3]. Apart from the rich polyphenolic profile, acylated oligosaccharides (integrisides A and B) were isolated from the butanol fraction of methanolic extract of *P. integerrima* [13]. Investigations unveiled that the ethyl acetate and chloroform fractions of *P. integerrima* confer strong cytotoxicity towards human breast cancer (MCF-7) cell line.

The current study deals with the isolation and purification of an efficacious phosphodiesterase-1 (PDE1) inhibitor from *P. integerrima* followed by docking studies.

2. Experimental

2.1. Sample Collection. *P. integerrima* galls were collected from Sultan Muhammad Razagram garden (district Dir,

K.P.K., Pakistan). The botanical sample was verified by Prof. Dr. A. Rashid (Botany Department, University of Peshawar, Pakistan). A voucher specimen (Bot 20037, PUP) was deposited in the department.

2.2. Extraction and Isolation. Shade-dried and crushed galls of *P. integerrima* were extracted with methanol. The extract was suspended in water and sequentially fractionated with *n*-hexane, chloroform, and ethyl acetate. The green residue from the chloroform fraction was subjected to column chromatography using silica gel. The elution of column was done using a mixture of methanol:chloroform (1:9, *v/v*). The fractions were combined according to their TLC profile into 10 different subfractions (PS-1 to PS-10). Fraction PS-10 was further subjected to repeated column chromatography and TLC, which furnished the compound 5-hydroxy-7-methoxy-2-(4-methoxyphenyl)-4*H*-chromen-4-one (compound 1). The structure of compound 1 (Figure 1) was confirmed by comparing its physical and spectral data with the previously reported compound [14].

2.3. Phosphodiesterase 1 Inhibition Assay. The activity of compound 1 against snake venom PDE1 (Sigma P-3134 manufactured from pit viper venom, EC 3.1.4.1) was assayed [15]. Tris-HCl buffer 33 mM (pH 8.8) and 30 mM magnesium acetate (cofactor) were added to 0.000742 U of PDE1 as a final concentration using a 96-well flat bottom plate and 0.33 mM bis-(*p*-nitrophenyl) phosphate (Sigma N-3002) as a substrate. Ethylenediamine tetra acetic acid (Merck), a chelating agent, was used as positive control. After 30 min of incubation, the enzyme activity was monitored at 37°C on a microtitre plate reader spectrophotometer (Molecular Devices, USA) by measuring the release of *p*-nitrophenol (a chromogenic product) from *p*-nitrophenyl phosphate (a nonproteinaceous, nonspecific substrate) at 410 nm. All the reactions were performed in triplicate, and the initial rates were measured as the rates of changes in the optical density (OD)/min and used in subsequent calculations [16].

$$\% \text{Inhibition} = 100 - \left(\frac{\text{OD}_{\text{testwell}}}{\text{OD}_{\text{control}}} \right) \times 100. \quad (1)$$

2.4. Homology Modeling. The snake venom PDE1 sequence was retrieved from Uniprot database (accession number of J3SEZ3) [17]. The template selection was carried out by BLAST against the Protein Data Bank (PDB) database [14, 15]. The crystal structure of *Mus musculus* (four-letter code: 4GTW) was obtained as the best hit according to its sequence identity [18]. The alignment of template and target sequence was carried out through BioEdit software [19]. The 3D model of PDE1 was generated through MODELLER 9.12 [20]. The predicted models were refined using energy optimization through Swiss PDB viewer v4.1.0 software [21]. The 3D structures were evaluated by ProSA [22] and Procheck online servers (Figure S1 a, b, and c) [23]. The best predicted model was selected for molecular docking studies.




FIGURE 1: Structure of compound 1 [5-hydroxy-7-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one]; (a) 2D and (b) 3D ball and stick model.

2.5. Docking Studies. Docking is the in silico prediction of the most favorable conformation of proteins in a complex by calculating the energy contained in the system, with the most accurate structure having the lowest energy [18]. The docking study for predicted model was carried out using two docking software, iGEMDOCK v 2.1 [19] and AutoDock Vina [20]. The docking procedure of both software was calibrated by already docked ligand in the receptor file. The 3D structure of compound 1 and EDTA was prepared by using Chem Draw [21]. The ligand was prepared through adjusting the chemical correctness (protonation) and stereochemical and ionization variation using computational tools. All the default parameters of iGEMDOCK software were used for the docking of compound 1 and EDTA against PDE1. The receptor file was cleaned from solvent molecules followed by hydrogen addition and Gasteiger partial charge calculation. The PDE1 3D model and ligands were uploaded in the PyRx tool [22]. The receptor and compound files were converted into PDBQT format (that holds information for the atomic coordinates, partial charges and solvation parameters for all the atoms in the molecule). The grid center of grid box was placed on the active site of the PDE1 receptor. The grid box of center $x = 30.28$, $y = 32.70$, and $z = 23.05$ and size of $x = 43.85 \text{ \AA}$, $y = 45.40 \text{ \AA}$, and $z = 49.29 \text{ \AA}$ with an exhaustiveness global search algorithm was set up to 8. The docked poses of predicted model PDE1 with compound 1 were analyzed by Discovery studio visualizer version 4.0 [24], PyMOL version 1.7.2 [25], and LIGPLOT+ version v.1.4.5 software [23, 26].

TABLE 1: Enzymes inhibitory activities of compound 1 and EDTA.

Compound	PDE1 inhibition (%) (0.2 mM)	IC ₅₀ ± S.E.M. (μM)
1	93.91	13.55 ± 0.04
EDTA	80.10	276.1 ± 2.65

3. Results

3.1. Results of PDE-1 Inhibition. The current study revealed the PDE1 inhibition potency of 5-hydroxy-7-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one (5-hydroxy-4',7-dimethoxy-flavone) isolated from *P. integerrima* galls. As shown in Table 1, the flavone elicited 93.9% inhibition at 0.2 mM concentration with outstanding potency (IC₅₀ 13.55 μM). EDTA exhibited 80.1% inhibition with IC₅₀ 276.1 μM .

3.2. Docking Studies. The analysis of docking simulation was carried out based upon the hydrogen bond and hydrophobic interactions. The interaction analysis indicated that compound 1 has good docking results compared to EDTA against PDE1. The docking result of compound 1 and EDTA are presented in Table 2. The predicted docking poses and superimposition of the compound 1 along with EDTA are shown in Figure 2. The interaction analysis of compound 1 (Figure 3) indicated that it forms two hydrogen bond interactions with Asn206 and Lys271 with a distance of 3.13 \AA and 3.14 \AA , respectively. Compound 1 also formed eleven hydrophobic contacts with residues Thr185, Phe186,

TABLE 2: The docking score and interaction profile of compound 1 and EDTA.

Compound	AutoDock Vina (kcal/mol)	GEM DOCK (kcal/mol)		Molecular interactions for compound 1	
	B. Affinity	Total energy	VDW	Hydrophobic	Hydrogen bonding
1	-7.6	-95	-82	Thr185, Phe186, Leu219, Phe250, Trp251, Pro252, Glu255,	Asn206 (3.13 Å)
EDTA	-6.5	-89	-60	Tyr269, Tyr300, Asp305, and Thr306	Lys271 (3.14 Å)




FIGURE 2: PDE1 predicted docked poses of compound 1 with ball and stick (cyan color), EDTA with stick (red color), and cocrystallized ligand with stick (green color).




FIGURE 3: (a) refers to the predicted dock pose of compound (1) with PDE1 while (b) displays the detailed schematic presentation of docked compound 1 against venom PDE1 with labelling of hydrogen bonding and hydrophobic interaction.

Leu219, Phe250, Trp251, Pro252, Glu255, Tyr269, Tyr300, Asp305, and Thr306. AutoDock Vina binding energy score for compound 1 was -7.6 kcal/mol, while it was -6.5 kcal/mol for EDTA (Table 2). The iGEMDOCK total energy

score for compound 1 was -95 kcal/mol, while it was -89 kcal/mol for EDTA (Table 2). The lower energy associated with compound 1 indicates its superior interacting capacity PDE1 receptor, compared to EDTA. This finding

appears interesting in this regard as the docking result proved the lowest energy associated with the ligand-protein binding. The isolated flavone merits *in vivo* assessment.

4. Discussion

Phosphodiesterases (PDEs) are nonspecific exonucleases, capable of hydrolyzing DNA, RNA, ATP, ADP, and NAD [27]. They catalyze the hydrolysis of phosphodiester bonds in cAMP and cGMP [28]. There are 11 different families of PDEs with specific substrate kinetic properties, mode of regulation, intracellular localization, and tissue expression patterns [29, 30]. They mediate diverse pathways such as the metabolism of extracellular nucleotides (nuclease activity), hydrolysis of nucleoside 5'-triphosphates (phosphatase activity), and regulation of nucleotide-based intercellular signaling. This enzyme in snake venom (vipers) perturbs homeostasis of the victim and aggregates plasma platelets causing blood coagulation. Hyperactivity of PDEs has been verified to drive arthritis, hypertension, and cardiovascular diseases [31]. Antivenom serum and metal chelator EDTA are known to inactivate PDEs [32]. Novel PDE inhibitors are sought after as a treatment for a range of inflammatory diseases. Natural phytochemical inhibitors have been reported to offer pharmacological properties such as smooth muscle relaxant, bronchodilator, vasodilator, antidepressant, antithrombotic, anti-inflammation, and cognitive promoter [30]. Methylxanthine was the first natural inhibitor of cyclic nucleotide PDEs. All PDE inhibitors contain one or more rings that mimic the purine in the cyclic nucleotide substrate and directly compete with it for access to the catalytic site [33]. Nobiletin, a polymethoxylated flavonoid extracted from citrus rind inhibited PDEs, elevating AMP level, and dopamine release. It assuaged memory malfunctioning in induced-Parkinson model mice [34]. *Forsythia suspensa* seed-derived lignin inhibited PDE4 in inflammatory and immune cells [35]. The mechanism was elucidated as the denaturation of PDE enzymes that influences cyclic adenosine monophosphate cAMP. An insightful review sheds light on the potency of PDE inhibitors to restore normalcy in dopamine signaling and thus treat motor, cognitive, and psychiatric disorders [29]. The provocative role of PDEs in airway smooth muscle inflammation and latest achievements in asthma and chronic obstructive pulmonary disease (COPD) management by targeting the enzyme was reviewed [36]. Drugs inhibiting PDE activity have a therapeutic action on the heart, lung, and vasculature as well as on platelet function and inflammatory mechanisms. These tissues express more multiple isoenzymes of PDEs. Thus, the drugs target more than one isoenzyme, which has undesirable consequences. For example, cilomilast ameliorates pulmonary functions but sets off gastrointestinal disturbances, emesis, and nausea [37]. Similarly, theophylline is used to treat respiratory problems, but when prescribed at higher concentrations, it causes cardiac arrhythmias and seizures [38]. It makes the quest for isoenzyme-selective inhibitors relevant. *In silico* docking studies were conducted for comparative modeling of PDE1 from snake venom, selected as the best predictive model. The molecular docking study of PDE1

was carried out through two docking software (iGEMDOCK and AutoDock Vina). The aim of this study was to validate the *in vitro* studies and identify the inhibitory specificity of compound 1 and efficacy in comparison to EDTA. Weak intermolecular interactions such as hydrogen bonding and hydrophobic interactions are crucial in stabilizing energetically favored ligands in protein structures. Therefore, quantification of the interaction energy between the target 3D structures and the ligand molecules is important to determine the affinity [17].

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors extend their appreciation to the Deanship of Scientific Research at King Khalid University for funding this work through Research group Project under grant number (R.G.P. 1/185/42).

Supplementary Materials

Figure S1: (a) and (b) refer to the ProSA result, and (c) represent the ProCheck result for best model evaluation and selection. (*Supplementary Materials*)

References

- [1] M. Zia, A. Waheed, S. Ahmed, M. F. Chaudhary, Y. Bibi, and S. Nisa, "The study of anticancer and antifungal activities of *Pistacia integerrima* extract in vitro," *Indian Journal of Pharmaceutical Sciences*, vol. 74, no. 4, 2012.
- [2] S. Ahmad, M. Ali, S. H. Ansari, and F. Ahmed, "Phytoconstituents from the galls of *Pistacia integerrima* Stewart," *Journal of Saudi Chemical Society*, vol. 14, no. 4, pp. 409–412, 2010.
- [3] R. Shirole, N. Shirole, A. Kshatriya, R. Kulkarni, and M. Saraf, "Investigation into the mechanism of action of essential oil of *Pistacia integerrima* for its antiasthmatic activity," *Journal of Ethnopharmacology*, vol. 153, no. 3, pp. 541–551, 2014.
- [4] H. Hosseinzadeh, E. Behravan, and M. M. Soleimani, "Antinociceptive and anti-inflammatory effects of *Pistacia vera* leaf extract in mice," *Iranian journal of pharmaceutical research: IJPR*, vol. 10, p. 821, 2011.
- [5] Y. Gerchman, "Antimicrobial activities in *Pistacia atlantica*—aphids make a difference!," *Multidisciplinary Digital Publishing Institute Proceedings*, vol. 66, 2020.
- [6] N. S. Ahmad, M. Farman, M. H. Najmi, K. B. Mian, and A. Hasan, "Pharmacological basis for use of *Pistacia integerrima* leaves in hyperuricemia and gout," *Journal of Ethnopharmacology*, vol. 117, no. 3, pp. 478–482, 2008.
- [7] Y. Bibi, S. Nisa, F. M. Chaudhary, and M. Zia, "Antibacterial activity of some selected medicinal plants of Pakistan," *BMC Complementary and Alternative Medicine*, vol. 11, pp. 1–7, 2011.

- [8] K. Mehla, S. Balwani, A. Kulshreshtha, D. Nandi, P. Jaisankar, and B. Ghosh, "Ethyl gallate isolated from *Pistacia integerrima* Linn. inhibits cell adhesion molecules by blocking AP-1 transcription factor," *Journal of Ethnopharmacology*, vol. 137, no. 3, pp. 1345–1352, 2011.
- [9] G. Uddin, A. Rauf, M. Arfan et al., "Pistagremic acid a new leishmanicidal triterpene isolated from *Pistacia integerrima* Stewart," *Journal of Enzyme Inhibition and Medicinal Chemistry*, vol. 27, no. 5, pp. 646–648, 2012.
- [10] G. Uddin, A. Rauf, A. M. Al-Othman et al., "Pistagremic acid, a glucosidase inhibitor from *Pistacia integerrima*," *Fitoterapia*, vol. 83, pp. 1648–1652, 2012.
- [11] A. Rauf, G. Uddin, B. S. Siddiqui et al., "In-vivo antinociceptive, anti-inflammatory and antipyretic activity of pistagremic acid isolated from *Pistacia integerrima*," *Phytomedicine*, vol. 21, no. 12, pp. 1509–1515, 2014.
- [12] A. Rauf, G. Uddin, and H. Khan, "Preliminary antioxidant profile of *Pistacia integerrima* Stewart," *Pakistan Journal of Pharmaceutical Sciences*, vol. 27, 2014.
- [13] Z. Ullah, R. Mehmood, M. Imran, A. Malik, and R. A. Afzal, "New acylated oligosaccharides from *Pistacia integerrima*," *Natural Product Research*, vol. 27, no. 21, pp. 2027–2032, 2013.
- [14] S. Bawazeer, A. Rauf, S. U. A. Shah et al., "Antioxidant and enzyme inhibitory activities of extracts and phytochemicals isolated from *Pistacia integerrima*," *Journal of Medicinal and Spice Plants*, vol. 23, pp. 55–58, 2019.
- [15] C. D. Fozing, Z. Ali, B. T. Ngadjui et al., "Phosphodiesterase I-inhibiting Diels-Alder adducts from the leaves of *Morus mesozygia*," *Planta Medica*, vol. 78, no. 2, pp. 154–159, 2012.
- [16] A. Rauf, M. Raza, M. Saleem et al., "Phosphodiesterase-1 inhibitory potential of several natural products by molecular docking approach," *Phytochemistry Letters*, vol. 30, pp. 356–361, 2019.
- [17] R. Patil, S. Das, A. Stanley, L. Yadav, A. Sudhakar, and A. K. Varma, "Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing," *PLoS One*, vol. 5, no. 8, article e12029, 2010.
- [18] D. Kozakov, K. Li, D. R. Hall et al., "Encounter complexes and dimensionality reduction in protein-protein association," *eLife*, vol. 3, article e01370, 2014.
- [19] D. S. Kaladhar, N. S. Yarla, and N. Anusha, "Functional analysis and molecular docking studies of medicinal compounds for AchE and BchE in Alzheimer's disease and type 2 diabetes mellitus," *Aging and Disease*, vol. 4, 2013.
- [20] O. Trott and A. J. Olson, "AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading," *Journal of Computational Chemistry*, vol. 30, pp. 455–461, 2010.
- [21] M. D. Hanwell, D. E. Curtis, D. C. Lonie, T. Vandermeersch, E. Zurek, and G. R. Hutchison, "Avogadro: an advanced semantic chemical editor, visualization, and analysis platform," *Journal of Cheminformatics*, vol. 4, pp. 1–17, 2012.
- [22] R. B. Jacob, T. Andersen, and O. M. McDougal, "Accessible high-throughput virtual screening molecular docking software for students and educators," *PLoS Computational Biology*, vol. 8, no. 5, article e1002499, 2012.
- [23] S. Khalid and S. Paul, "Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: A plausible therapeutic approach in Alzheimer's disease," *Medical Hypotheses*, vol. 83, no. 1, pp. 39–46, 2014.
- [24] D. Studio, "Discovery studio," Accelrys [2.1], 2008.
- [25] W. L. DeLano, "Molecular docking of selective binding affinity of sulfonamide derivatives as potential antimalarial agents targeting the glycolytic enzymes: GAPDH, aldolase and TPI," *Open Journal of Biophysics*, vol. 7, no. 1, pp. 47–57, 2017.
- [26] R. A. Laskowski and M. B. Swindells, *LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery*, ACS Publications, 2011.
- [27] K. Trummal, A. Aaspõllu, K. Tõnismägi et al., "Phosphodiesterase from *Vipera lebetina* venom-structure and characterization," *Biochimie*, vol. 106, pp. 48–55, 2014.
- [28] P. Acharya, *Ion channel signaling: a short review*, vol. 7, 2017.
- [29] C. Gonzalez, H. Rosas-Hernandez, M. A. Ramirez-Lee, S. Salazar-García, and S. F. Ali, "Role of silver nanoparticles (AgNPs) on the cardiovascular system," *Archives of Toxicology*, vol. 90, pp. 493–511, 2016.
- [30] R. Rahimi, S. Ghiasi, H. Azimi, S. Fakhari, and M. Abdollahi, "A review of the herbal phosphodiesterase inhibitors; future perspective of new drugs," *Cytokine*, vol. 49, pp. 123–129, 2010.
- [31] K. M. Khan, S. Siddiqui, M. Saleem et al., "Synthesis of triazole Schiff bases: novel inhibitors of nucleotide pyrophosphatase/phosphodiesterase-1," *Bioorganic & Medicinal Chemistry*, vol. 22, pp. 6509–6514, 2014.
- [32] J. Mitra and D. Bhattacharyya, "Phosphodiesterase from *Daboia russelli russelli* venom: purification, partial characterization and inhibition of platelet aggregation," *Toxicon*, vol. 88, pp. 1–10, 2014.
- [33] B. B. Fredholm, S. H. Francis, K. R. Sekhar, H. Ke, and J. D. Corbin, "Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds," *Methylxanthines*, vol. 200, pp. 93–133, 2011.
- [34] Y. Yabuki, Y. Ohizumi, A. Yokosuka, Y. Mimaki, and K. Fukunaga, "Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice," *Neuroscience*, vol. 259, pp. 126–141, 2014.
- [35] T. A. Coon, A. C. McKelvey, N. M. Weathington et al., "Novel PDE4 inhibitors derived from Chinese medicine forsythia," *PLoS One*, vol. 9, no. 12, article e115937, 2014.
- [36] C. P. Page, "Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease," *International Archives of Allergy and Immunology*, vol. 165, pp. 152–164, 2015.
- [37] K. F. Rabe, "Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease," *British Journal of Pharmacology*, vol. 163, no. 1, pp. 53–67, 2011.
- [38] P. J. Barnes, "Theophylline," *American Journal of Respiratory and Critical Care Medicine*, vol. 188, no. 8, pp. 901–906, 2013.